Gene · 10643
Papers3,038
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
921 to 940 of 3,038
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| N6-methyladenosine modification of viral RNA and its role during the recognition process of RIG-I-like receptors. | Front Immunol | 2022 | 36582239 | PubTator, text mining | PubMed |
| Diagnostic gene signatures and aberrant pathway activation based on m6A methylation regulators in rheumatoid arthritis. | Front Immunol | 2022 | 36582238 | PubTator, text mining | PubMed |
| m6A RNA methylation regulator-based signature for prognostic prediction and its potential immunological role in uterine corpus endometrial carcinoma. | BMC Cancer | 2022 | 36581816 | PubTator, text mining | PubMed |
| Genome-wide association study of the response of patients with diabetic macular edema to intravitreal Anti-VEGF injection. | Sci Rep | 2022 | 36581632 | PubTator, text mining | PubMed |
| METTL14 Regulates Intestine Cellular Senescence through m6A Modification of Lamin B Receptor. | Oxid Med Cell Longev | 2022 | 36578521 | PubTator, text mining | PubMed |
| The Role of N6-Methyladenosine in Inflammatory Diseases. | Oxid Med Cell Longev | 2022 | 36578520 | PubTator, text mining | PubMed |
| The utility of IMP3 immunohistochemical staining in differentiating nodular lymphocyte predominant Hodgkin Lymphoma from T-Cell/Histiocyte-Rich large B-Cell lymphoma. | BMC Cancer | 2022 | 36577979 | PubTator, text mining | PubMed |
| The regulatory role of N6-methyladenosine RNA modification in gastric cancer: Molecular mechanisms and potential therapeutic targets. | Front Oncol | 2022 | 36561529 | PubTator, text mining | PubMed |
| Engagement of the G3BP2-TRIM25 Interaction by Nucleocapsid Protein Suppresses the Type I Interferon Response in SARS-CoV-2-Infected Cells. | Vaccines (Basel) | 2022 | 36560452 | PubTator, text mining | PubMed |
| RNA Epigenetics in Chronic Lung Diseases. | Genes (Basel) | 2022 | 36553648 | PubTator, text mining | PubMed |
| Molecular Landscape of Pediatric Thyroid Cancer: A Review. | Diagnostics (Basel) | 2022 | 36553142 | PubTator, text mining | PubMed |
| Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis. | Front Endocrinol (Lausanne) | 2022 | 36545327 | PubTator, text mining | PubMed |
| RNA methylation in vascular disease: a systematic review. | J Cardiothorac Surg | 2022 | 36536469 | PubTator, text mining | PubMed |
| HNRNPC, a predictor of prognosis and immunotherapy response based on bioinformatics analysis, is related to proliferation and invasion of NSCLC cells. | Respir Res | 2022 | 36536402 | PubTator, text mining | PubMed |
| Biological and pharmacological roles of m6A modifications in cancer drug resistance. | Mol Cancer | 2022 | 36517820 | PubTator, text mining | PubMed |
| Expression patterns of platinum resistance-related genes in lung adenocarcinoma and related clinical value models. | Front Genet | 2022 | 36506331 | PubTator, text mining | PubMed |
| The Transcriptome and Proteome Networks of Malignant Tumours Reveal Atavistic Attractors of Polyploidy-Related Asexual Reproduction. | Int J Mol Sci | 2022 | 36499258 | PubTator, text mining | PubMed |
| Comprehensive Pan-Cancer Analyses of Immunogenic Cell Death as a Biomarker in Predicting Prognosis and Therapeutic Response. | Cancers (Basel) | 2022 | 36497433 | PubTator, text mining | PubMed |
| Biological Functions of the DNA Glycosylase NEIL3 and Its Role in Disease Progression Including Cancer. | Cancers (Basel) | 2022 | 36497204 | PubTator, text mining | PubMed |
| circPLIN2 promotes clear cell renal cell carcinoma progression by binding IGF2BP proteins and miR-199a-3p. | Cell Death Dis | 2022 | 36494341 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10643/papers?page=47